
|Videos|July 15, 2020
The Evolving Role of Tucatinib in HER2-Positive Metastatic Breast Cancer
Author(s)Sara A. Hurvitz, MD
A key opinion leader discusses how the role tucatinib is evolving in the management of HER2-positive metastatic breast cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5

















